Paydirt
SK
Insider

Samuel Kintz

PRESIDENT AND CEO

Samuel Kintz (PRESIDENT AND CEO) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $273K of ELVN (12,500 sh × $21.82, as filed), executed Nov 17 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
returns measure stock purchases only
Filings, ttm
2
0 buys · 2 sells
Median delay
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$539K
shares × price, as filed
Last traded
Nov 17 2025
Filed Nov 19 2025

Median ADV $83.7M across their filed names

Open performance
Volume by month
$1.1M$547K$0Oct 2024Apr 2025Oct 2025Apr 2026Oct 2024 · sells $1.1MMar 2025 · sells $260KMay 2025 · sells $107KJun 2025 · sells $382KJul 2025 · sells $106KAug 2025 · sells $208KOct 2025 · sells $267KNov 2025 · sells $273K
Buys $0 Sells $2.7M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 2 filings

Sector per market data · by filing · past 12 months

Most traded names
ELVN Enliven Therapeutics, Inc. ELVN · 0 buys · 10 sells 10 filings
Recent filings
ELVNSALE Enliven Therapeutics, Inc. View filing → $758K
27,047 sh across 2 lots
Exec Oct 8 2024
Filed Oct 10 2024 · 5:30 PM ET
ELVNSALE Enliven Therapeutics, Inc. View filing → $336K
12,206 sh × $27.51
Exec Oct 4 2024
Filed Oct 8 2024 · 5:30 PM ET